FDA review vouchers

New England Journal of Medicine

Volumn 360, Issue 8, 2009, Pages 837-838

  Moe, Jeffrey ^a   Grabowski, Henry ^a   Ridley, David ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; LETTER; MALARIA; PRIORITY JOURNAL; TROPICAL DISEASE; TUBERCULOSIS;

EID: 78650421279     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc086492     Document Type: Letter

References (4)

1. Kesselheim AS. Drug development for neglected diseases - the trouble with FDA review vouchers. N Engl J Med 2008;359:1981-3.
2. Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Aff (Millwood) 2006;25:313-24.
3. Grabowski HG, Wang YR. Do faster Food and Drug Administration drug reviews adversely affect patient safety? An analysis of the 1992 Prescription Drug User Fee Act. J Law Econ 2008;51:377-406.
4. Berndt ER, Glennerster R, Kremer MR, et al. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Econ 2007;16:491-511.